Firm’s dual path immunoassay platform will be used in conjunction with Infectious Disease Research Institute’s antigens.
Chembio Diagnostics and the Infectious Disease Research Institute (IDRI) entered into two R&D deals related to diagnostic tests for leishmaniasis and leprosy. Chembio will use its dual path immunoassay test platform, DPP™ and will incorporate IDRI’s antigens.
Chembio reports that in preliminary studies during the first quarter of 2007, superior analytical sensitivity on certain well-characterized samples from patients with these diseases were observed.
The organizations expect to complete prototype tests this year and then intend to seek commitments for procurement of these products for affected populations globally.
IDRI receives funding from the NIH and the Bill and Melinda Gates Foundation for the development of vaccines and diagnostics for leishmaniasis and from the American Leprosy Mission for similar activities in leprosy.
